Retrieved on:
Thursday, February 29, 2024
Incidence,
Hospital,
Disability,
4.0,
CMS,
PMA,
MDR,
FDA,
Quality of life,
Food,
Growth,
Defense,
Amputation,
Disclosure,
Bionics,
Center of excellence,
Mercedes-Benz Axor,
Syndrome,
Medicare,
Certification,
Ecosystem,
Patient,
Trial of the century,
Osseointegration,
Medical device The growth in the US market is 43% compared with the corresponding period last year.
Key Points:
- The growth in the US market is 43% compared with the corresponding period last year.
- The third quarter has been characterized by record sales figures, mainly driven by our continued expansion in the US and a recent accelerating growth in emerging markets.
- Integrum is the world's foremost company in in advanced amputation treatment, and we look forward to leading the way in restoring mobility globally.
- This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).
Retrieved on:
Thursday, February 1, 2024
MÖLNDAL, Sweden, Jan. 31, 2024 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.
Key Points:
- MÖLNDAL, Sweden, Jan. 31, 2024 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.
- Integrum helped establish the Center of Excellence in December 2023, and two senior surgeons have been trained and certified to perform surgeries on both transfemoral and transhumeral amputees using Integrum's innovative OPRA™ Implant System.
- Following a successful establishment, the Center of Excellence today completed a major purchase to secure continuous access to the OPRA Implant System.
- This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).
Restitutio ad integrum,
Food,
Elective surgery,
Unitary patent,
SEK,
US Foods,
Risk,
Patient,
Mercedes-Benz Axor,
FDA,
Marketing,
USD,
Ryan AbilityLab,
CMS,
NIH,
Trauma,
Trial of the century,
Amputation,
Growth,
Medicare,
Bangladesh Technical Education Board,
PMA,
Patent,
Life insurance,
Cryptocurrency,
Health insurance,
Medical device,
Pharmaceutical industry,
Application The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.
Key Points:
- The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.
- Our second quarter has been intense with record sales, increased operating profit and a number of great achievements that will help drive the business forward.
- During the quarter, Integrum made a restructuring of the company´s sales and marketing organization to fully focus on executing growth in the US.
- At the end of October, Integrum signed a distribution agreement for the Turkish market which generated sales of 1.3 MSEK.
Retrieved on:
Friday, November 10, 2023
MÖLNDAL, Sweden, Nov. 10, 2023 /PRNewswire/ -- For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added.
Key Points:
- MÖLNDAL, Sweden, Nov. 10, 2023 /PRNewswire/ -- For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added.
- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.
- The complete result for Integrum will be presented in the quarterly report for August - October 2023 which is published on December 4, 2023.
- This disclosure contains information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014).
MÖLNDAL, Sweden, Oct. 30, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company's OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US.
Key Points:
- MÖLNDAL, Sweden, Oct. 30, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company's OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US.
- The clinical study will be important for the future approval of the OPRA™ Implant System on the below-knee amputation level, which is the most frequent amputation level.
- The study will be performed by the Walter Reed National Military Medical Center.
- "This is an important milestone in the expansion of indications for our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.
MÖLNDAL, Sweden, Oct. 27, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.
Key Points:
- MÖLNDAL, Sweden, Oct. 27, 2023 /PRNewswire/ -- Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.
- As part of Integrum's efforts to expand the availability of the OPRA™ Implant System to new geographical markets, the company has as of today started a collaboration in Turkey with Medikon ( www.medikon.net ).
- "The collaboration with Medikon secures a foothold in the Turkish market for Integrum's unique solutions, a country where orthopedic healthcare is strongly marked by the earthquake that occurred earlier this year.
- There is a great need for innovative orthopedic solutions, and we are happy to be able to help improve the quality of life for amputees with our OPRA™ Implant System," said Rickard Brånemark, CEO of Integrum.
